Biopharma · FDA Approvals · Stock
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug developme…
Assets on file: PAS-004
Dated catalysts for KTTA, including recently decided ones.
Nothing scheduled in this window.
Every first-hand event for KTTA, newest first.
Pasithea Reports Positive Phase 1/1b Data for PAS-004 in NF1-Associated Neurofibromas
Pasithea presented initial Phase 1/1b results showing tumor reductions in all evaluable patients with cNF (median 41-46%) and PN, deepening over time, with a favorable safety profile. The FDA cleared the IND for a Phase 2 trial in cNF. This is the first public report of these clinical results.
Pasithea receives FDA Orphan Drug Designation for PAS-004 in ALS
FDA granted Orphan Drug Designation to PAS-004 for ALS, conferring tax credits, fee exemptions, and seven-year market exclusivity eligibility. The designation supports further development of the macrocyclic MEK inhibitor in ALS and other MAPK-driven diseases. No PDUFA date or additional regulatory timeline was announced.
Companies in the same sector closest to KTTA in market value.